Current approaches to therapy for complications of bone metastases from breast cancer
https://doi.org/10.17650/1994-4098-2014-0-1-36-41
Abstract
In breast cancer, bone metastases are detectable in more than 60 % of patients. Bone metastasis-related complications (BMRCs), such as chronic pain, immobilization, and pelvic dysfunctions due to spinal cord compression, considerably worsen quality of life in patients. Intra- venous formulations of bisphosphonates (zoledronic acid, pamidronate, ibondronate, and clodronate) could reduce the risk of BMRCs by 16-40 % and increase time to the first skeletal complication up to 12–13 months. However, despite the explicit clinical efficacy of bisphospho- nates, the latter can seemingly prevent only some BMRCs. Denosumab, a fully human monoclonal antibody to RANKL, suppresses the forma- tion and functional activity of osteoclasts, thus inhibiting bone resorption.
The results of a registration study have indicated that denosumab is not only as effective as zoledronic acid, but also can reduce the risk of BMRCs and significantly delay time to the first and further skeletal complications, including the need for radiotherapy, the development of hypercalcemia and pathological fractures. Denosumab is an effective, well-tolerated drug that can increase a chance of preventing BMRCs in breast cancer.
About the Author
L. G. Zhukova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Инструкция по медицинскому примене- нию препарата Эксджива (XGEVA) в Российской Федерации. РУ ЛП-000871Б http://www.webvidal.ru/DescrDrug. aspx?ID=32105.
2. Coleman R.E. Metastatic bone disease: сlinical features, pathophysiology, and treatment strategies. Cancer Treat Rev 2001;27(3):165–76.
3. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2(8):584–93.
4. Hortobagyi G.N., Theriault R.L., Lipton A. et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin
5. Oncol 1998;16(6):2038–44.
6. Lipton A. Bisphosphonates and breast carcinoma Present and future. Cancer 2000;88(12 Suppl):3033–7.
7. Rosen L.S., Gordon D.H., Dugan W. Jr. et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100(1):36–43.
8. Hillner B.E., Ingle J.N., Chlebowski R.T. et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in breast cancer. J Clin Oncol 2003;21(21):4042–57.
9. Rosen L.S., Gordon D., Tchekmedyian N.S. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors:
10. a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100(12):2613–21.
11. Rosen L.S., Gordon D.H., Dugan W. Jr. et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100(1):36–43.
12. Saad F., Gleason D.M., Murray R.J. et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96(11):879–82. 11. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004;350(16):1655–64. 12. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003;423(6937):337–42.
13. Lipton A., Steger G.G., Figueroa J. et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25(28):4431–7.
14. Lipton A., Steger G.G., Figueroa J. et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. J Clin Cancer Res 2008;14(20):6690–6.
15. LewieckiE.M.Safetyandtolerability of denosumab for the treatment of postmenopausal osteoporosis. Drug Healthc Patient Saf 2011;3:79–91.
16. Chung K.С., Barlev A., Braun A.Н. et al. Development of the analgesic quantification algorithm (AQA): a new scale to assess analgesic use. Eur J Can Suppl 2009;7: 186 (abstr P-3037).
17. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79.
18. Eton D.T., Cella D., Yost K.J. et al. A combination of distribution- and anchor- based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004;57(9):898–910.
19. Martin M., Bell R., Bourgeois H. et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer
20. Res 2012;18(17):4841–9.
21. Stopeck A.Т., Lipton A., Body J.J. et.al. Denosumab сompared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28(35):5132–9.
22. Brown J.E., Neville-Webbe H., Coleman R.E. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004;11(2):207–24.
23. Hu M.I., Glezerman I., Leboulleux S. et al. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst 2013;105(18):1417–20.
Review
For citations:
Zhukova L.G. Current approaches to therapy for complications of bone metastases from breast cancer. Tumors of female reproductive system. 2014;(1):36-41. (In Russ.) https://doi.org/10.17650/1994-4098-2014-0-1-36-41
Views:
750
Email this article 